Research Paper Volume 16, Issue 11 pp 10033—10062
A new perspective: deciphering the aberrance and clinical implication of disulfidptosis signatures in clear cell renal cell carcinoma
Figure 12. Relationship between DRS and immunotherapy. (A, B) Survival analysis for overall survival and progression-free survival of the two DRS groups in patients with ccRCC who were treated with nivolumab from the RCC-Braun_2020 cohort. (C) Comparison of DRS of different patients with ccRCC in different remission states after immunotherapy in RCC-Braun_2020 cohort. (ns, p > 0.05; *p < 0.05).